Market Price

8.29 

0.19 2.4%

as of Mar 20 '19

52 Week Range:

4.87 8.70


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

KAINOS Laboratories, Inc. develops, manufactures, markets, distributes, and imports/exports pharmaceuticals, diagnostic reagents, related chemical products, physical and chemical measurement instruments, medical supplies, nutrition supplements, foodstuff, animal feed, and related products in Japan. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos series for automated analysis equipment; Lana 1,5AG, a high-sensitivity diabetes diagnostic reagent and a family of immunoserological testing reagents; MAST, an allergic diagnostic reagent; and Hitazyme Chlamydia for infectious diseases. It also provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum; biochemical diagnostic reagents, including Aqua-auto Kainos UN-II test kit, a liquid form urea nitrogen measurement reagent kit; and Aqua-auto Kainos CRE-II test kit, a liquid form creatinine measurement reagent kit. In addition, the company offers Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick-N for detecting Type A and Type B influenza virus antigens; and Statmark Strep A for detecting Group A-b hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 4.39
4.79
5.15
5.62
5.32
4.85
5.63
6.24
7.28
7.03
growth rate 9.1% 7.5% 9.1% -5.3% -8.8% 16.1% 10.8% 16.7% -3.4%
Earnings BIT 47.45
20.77
201.81
growth rate -56.2% 871.9%
Avg.PE 31.78
27.53
30.00
growth rate -13.4% 9.0%
ROA 0.08
3.06
1.80
1.31
1.96
2.60
3.17
3.74
4.89
5.29
4.65
growth rate 3,725.0% -41.2% -27.2% 49.6% 32.7% 21.9% 18.0% 30.8% 8.2% -12.1%
ROE 0.17
6.75
3.88
2.81
4.13
5.40
6.45
7.24
8.93
8.86
7.41
growth rate 3,870.6% -42.5% -27.6% 47.0% 30.8% 19.4% 12.3% 23.3% -0.8% -16.4%
ROIC 0.59
4.23
2.70
2.06
2.87
3.70
4.51
5.20
6.62
6.82
5.91
growth rate 617.0% -36.2% -23.7% 39.3% 28.9% 21.9% 15.3% 27.3% 3.0% -13.3%
Cur. Ratio 0.96
1.04
1.04
1.02
0.92
1.13
1.18
1.20
1.48
1.65
1.62
growth rate 8.3% 0.0% -1.9% -9.8% 22.8% 4.4% 1.7% 23.3% 11.5% -1.8%
Quick Ratio 0.69
0.87
0.86
0.87
0.75
0.91
0.98
0.99
1.19
1.33
1.31
growth rate 26.1% -1.2% 1.2% -13.8% 21.3% 7.7% 1.0% 20.2% 11.8% -1.5%
Leverage 2.23
2.17
2.14
2.15
2.08
2.09
1.98
1.89
1.76
1.59
1.59
growth rate -2.7% -1.4% 0.5% -3.3% 0.5% -5.3% -4.6% -6.9% -9.7% 0.0%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 830.19
844.82
1,029.47
growth rate 1.8% 21.9%
Acct.Payable 761.79
815.65
976.40
growth rate 7.1% 19.7%
Cur.Assets 1,934.84
2,260.85
2,322.49
growth rate 16.9% 2.7%
Total Assets 5,371.95
5,574.79
5,677.39
growth rate 3.8% 1.8%
Cash 441.53
708.14
563.75
growth rate 60.4% -20.4%
Inventory 468.40
305.17
313.61
growth rate -34.9% 2.8%
Cur.Liabilities 2,023.30
2,177.66
2,239.44
growth rate 7.6% 2.8%
Liabilities 2,966.07
3,008.93
3,019.05
growth rate 1.5% 0.3%
LT Debt 859.87
745.71
688.66
growth rate -13.3% -7.7%
Equity 2,405.88
2,565.86
2,658.34
growth rate 6.7% 3.6%
Common Shares 831.41
4.00
4.00
4.00
4.00
4.00
4.00
4.00
4.00
4.00
4.00
growth rate -99.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 19.73
10.33
30.10
growth rate -47.6% 191.4%
Cash Dividends 33.21
0.11
17.89
growth rate -99.7% 16,463.9%
Cash From OA 203.04
183.68
129.79
growth rate -9.5% -29.3%
FCF per Share 0.16
0.30
0.18
0.55
0.34
-0.08
0.46
0.56
0.32
0.69
0.27
growth rate 87.5% -40.0% 205.6% -38.2% -100.0% 100.0% 21.7% -42.9% 115.6% -60.9%
FCF 113.00
173.00
98.00
286.00
-83.00
245.00
344.00
353.00
139.00
303.00
167.00
growth rate 53.1% -43.4% 191.8% -100.0% 100.0% 40.4% 2.6% -60.6% 118.0% -44.9%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 3,959.78
3,594.89
4,215.05
growth rate -9.2% 17.3%
Op.Income 47.45
20.77
201.81
growth rate -56.2% 871.9%
IBT 33.45
291.51
179.32
growth rate 771.5% -38.5%
Net Income 4.15
167.72
101.44
growth rate 3,940.5% -39.5%
EPS 0.93
37.64
22.77
16.90
25.42
34.57
43.37
51.73
69.39
74.12
66.49
growth rate 3,947.3% -39.5% -25.8% 50.4% 36.0% 25.5% 19.3% 34.1% 6.8% -10.3%
Gross Profit 1,375.30
1,281.45
1,519.95
growth rate -6.8% 18.6%
R&D 209.11
204.84
196.49
growth rate -2.0% -4.1%

Quarterly Statements

Item Name Mar '10 Jun '10 Sep '10 Dec '10
Earnings BIT 30.07
51.48
61.01
58.42
growth rate 71.2% 18.5% -4.3%
Balance Sheet Mar '10 Jun '10 Sep '10 Dec '10
Acct.Receivable 1,029.47
1,030.08
953.22
1,001.39
growth rate 0.1% -7.5% 5.1%
Acct.Payable 976.40
833.28
713.51
795.93
growth rate -14.7% -14.4% 11.6%
Cur.Assets 2,322.49
2,471.03
2,172.34
2,412.01
growth rate 6.4% -12.1% 11.0%
Total Assets 5,677.39
5,794.94
5,602.96
5,724.01
growth rate 2.1% -3.3% 2.2%
Cash 563.75
731.77
490.77
692.91
growth rate 29.8% -32.9% 41.2%
Inventory 313.61
318.36
322.99
325.77
growth rate 1.5% 1.5% 0.9%
Cur.Liabilities 2,239.44
2,328.74
2,244.51
2,365.93
growth rate 4.0% -3.6% 5.4%
Liabilities 3,019.05
3,178.91
2,953.31
3,039.64
growth rate 5.3% -7.1% 2.9%
LT Debt 688.66
732.51
590.59
549.11
growth rate 6.4% -19.4% -7.0%
Equity 2,658.34
2,616.03
2,649.65
2,684.37
growth rate -1.6% 1.3% 1.3%
Common Shares 831.41
831.41
831.41
831.41
growth rate 0.0% 0.0% 0.0%
Cash Flow Statement Mar '10 Jun '10 Sep '10 Dec '10
Capital Expenditures 26.83
26.58
14.27
11.77
growth rate -0.9% -46.3% -17.5%
Cash Dividends 33.45
33.45
0.19
0.01
growth rate 0.0% -99.4% -96.8%
Cash From OA 67.69
56.47
66.94
86.21
growth rate -16.6% 18.5% 28.8%
FCF 40.86
29.89
52.67
74.43
growth rate -26.8% 76.2% 41.3%
Income Statement Mar '10 Jun '10 Sep '10 Dec '10
Sales 1,092.24
1,133.09
1,073.10
1,138.18
growth rate 3.7% -5.3% 6.1%
Op.Income 30.07
51.48
61.01
58.42
growth rate 71.2% 18.5% -4.3%
IBT 24.35
-2.52
54.41
57.34
growth rate -100.0% 100.0% 5.4%
Net Income 22.17
-6.43
33.10
33.91
growth rate -100.0% 100.0% 2.5%
Gross Profit 368.19
373.16
406.92
403.14
growth rate 1.4% 9.1% -0.9%
R&D 196.49
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (19.94)

YOY Growth Grade:

F (13.91)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 45.33 49.05
EPS / Growth 0.17

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 3.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 3.8% 3.8% 3.8%
Future PE 0.01 3.81 3.81
Future EPS 0.25 0.25 0.25
Value Price
MOS %
0.00
-100.0%
0.23
-97.2%
0.23
-97.2%
MOS Price 0.00 0.12 0.12
IRT 27.56 27.56 27.56

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.